89bio announces publication of results of phase 1b/2a study of pegozafermin for the treatment of nash in the lancet gastroenterology & hepatology

– data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver injury, fibrosis and lipids –

ETNB Ratings Summary

ETNB Quant Ranking